All In MedTech

Device Trial Radar · NCT07568015

ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain

ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain: A Multi-Center, Randomized, Controlled Trial (RENEU)

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

Jul 27, 2026

Primary completion

Nov 1, 2027

Study completion Nov 1, 2029

Sponsor

Lead sponsor
Brixton Biosciences, Inc.Not on our public-company list
Sponsor type
Industry
Collaborators
MCRA
First posted
May 5, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 22 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety and analgesic performance of the ReneuRx™ device in subjects with moderate to severe chronic lateral hip pain compared to subjects receiving treatment with corticosteroid injection in adults aged 22-80 years. Participants will attend study visits and complete quality of life questionnaires. Participants will be followed for approximately 6-12 months after the study procedure.

Conditions

  • Greater Trochanteric Pain Syndrome
  • Greater Trochanteric Pain Syndrome of Both Lower Limbs
  • Lateral Hip Pain

Interventions

  • Triamcinolone acetateDrug

    A single 40mg Triamcinolone dose, prepared as 1ml of steroid mixed with 4ml of saline, of which 3-5ml is injected.

  • ReneuRxDevice

    ReneuRx will be injected around the trochanteric branches of the femoral nerve.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary EffectivenessTime frame: 3-months post treatment
  2. Primary SafetyTime frame: Through study completion, an average of 12-months

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Healthcare Outcomes Performance Company

    Sun City, Arizona · Recruiting

  • Emory Orthopedics and Spine Center

    Johns Creek, Georgia · Not yet recruiting

  • Ochsner Health Center

    New Orleans, Louisiana · Not yet recruiting

8 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.